Alzheimer's Disease International (ADI). World Alzheimer Report 2019: Attitudes to dementia. https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf. Accessed 27 May 2022.

Alzheimer's Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021;17:327–406.

Article  CAS  Google Scholar 

Cavazzoni P. FDA’s decision to approve new treatment for Alzheimer’s disease. https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease. Accessed 31 Mar 2022.

Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, et al. Aducanumab: Appropriate use recommendations. J Prev Alzheimers Dis. 2021;8:398–410.

Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020;6:e12050.

Google Scholar 

Dubois B, Padovani A, Scheltens P, Rossi A, Dell'Agnello G. Timely diagnosis for Alzheimer’s disease: A literature review on benefits and challenges. J Alzheimers Dis. 2016;49:617–31.

PubMed  Article  Google Scholar 

Glaab E, Rauschenberger A, Banzi R, Gerardi C, Garcia P, et al. Biomarker discovery studies for patient stratification using machine learning analysis of omics data: A scoping review. BMJ Open. 2021;11:e053674.

PubMed  PubMed Central  Article  Google Scholar 

Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with subtype and stage inference. Nat Commun. 2018;9:4273.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Barton A, Pitzalis C. Stratified medicine in rheumatoid arthritis-the MATURA programme. Rheumatology (Oxford). 2017;56:1247–50.

Article  Google Scholar 

Cousins H, Cousins C. A framework for patient stratification in clinical trials for Alzheimer’s disease. J Alzheimers Neurodegener Dis. 2020;6:033.

Article  Google Scholar 

Cerezo Cerezo J, Arias López C. Population stratification: A fundamental instrument used for population health management in Spain: good practice brief. https://apps.who.int/iris/handle/10665/345586. Accessed 31 Mar 2022.

Coran JJ, Schario ME, Pronovost PJ. Stratifying for value: An updated population health risk stratification approach. Popul Health Manag. 2022;25:91–9.

PubMed  Article  Google Scholar 

Russnes HG, Lingjærde OC, Børresen-Dale AL, Caldas C. Breast cancer molecular stratification: From intrinsic subtypes to integrative clusters. Am J Pathol. 2017;187:2152–62.

CAS  PubMed  Article  Google Scholar 

American Cancer Society. Breast cancer facts & figures 2019-20. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf. Accessed 31 Mar 2022.

Ying L, Yan F, Xu D. Cancer patient stratification based on the tumor microenvironment. J Thorac Dis. 2020;12:4522–6.

PubMed  PubMed Central  Article  Google Scholar 

Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, et al. Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group. Lancet Neurol. 2021;20:484–96.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.

Ferretti MT, Martinkova J, Biskup E, Benke T, Gialdini G, et al. Sex and gender differences in Alzheimer's disease: current challenges and implications for clinical practice: Position paper of the dementia and cognitive disorders panel of the European Academy of Neurology. Eur J Neurol. 2020;27:928–43.

Seidl JN, Massman PJ. Rapidly versus slowly progressing patients with Alzheimer’s disease: Differences in baseline cognition. Am J Alzheimers Dis Other Dement. 2016;31:318–25.

Liu J, Hlávka J, Hillestad R, Mattke S. Assessing the preparedness of the US health care system infrastructure for an Alzheimer’s treatment: RAND Corporation; 2017. Online only:1-16.

Reitz C. Toward precision medicine in Alzheimer’s disease. Ann Transl Med. 2016;4:107.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Li JQ, Tan L, Wang HF, Tan MS, Tan L, et al. Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies. J Neurol Neurosurg Psychiatry. 2016;87:476–84.

PubMed  Article  Google Scholar 

Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: Meta-analysis. Acta Psychiatr Scand. 2014;130:439–51.

Gulpers B, Ramakers I, Hamel R, Köhler S, Voshaar RO, et al. Anxiety as a predictor for cognitive decline and dementia: A systematic review and meta-analysis. Am J Geriatr Psychiatry. 2016;24:823–42.

PubMed  Article  Google Scholar 

Espinosa A, Alegret M, Valero S, Vinyes-Junqué G, Hernández I, et al. A longitudinal follow-up of 550 mild cognitive impairment patients: Evidence for large conversion to dementia rates and detection of major risk factors involved. J Alzheimers Dis. 2013;34:769–80.

PubMed  Article  Google Scholar 

Espinosa A, Alegret M, Pesini P, Valero S, Lafuente A, et al. Cognitive composites domain scores related to neuroimaging biomarkers within probable-amnestic mild cognitive impairment-storage subtype. J Alzheimers Dis. 2017;57:447–59.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Risacher SL, Saykin AJ. Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol. 2013;33:386–416.

PubMed  PubMed Central  Article  Google Scholar 

Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15:888–98.

PubMed  PubMed Central  Article  Google Scholar 

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396:413–46.

PubMed  PubMed Central  Article  Google Scholar 

Hampel H, Vergallo A, Giorgi FS, Kim SH, Depypere H, et al. Precision medicine and drug development in Alzheimer’s disease: the importance of sexual dimorphism and patient stratification. Front Neuroendocrinol. 2018;50:31–51.

PubMed  Article  Google Scholar 

Hlávka JP, Mattke S, Liu JL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer’s treatment. Rand Health Q. 2019;8:2.

PubMed  PubMed Central  Google Scholar 

National Collaborating Centre for Mental Health. The Dementia Care Pathway. https://www.rcpsych.ac.uk/docs/default-source/improving-care/nccmh/dementia/nccmh-dementia-care-pathway-full-implementation-guidance.pdf?sfvrsn=cdef189d_8. Accessed 31 Mar 2022.

Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67–77.

PubMed  PubMed Central  Article  Google Scholar 

Niemantsverdriet E, Valckx S, Bjerke M, Engelborghs S. Alzheimer’s disease CSF biomarkers: Clinical indications and rational use. Acta Neurol Belg. 2017;117:591–602.

PubMed  PubMed Central  Article  Google Scholar 

Nordberg A, Rinne JO, Kadir A, Långström B. The use of PET in Alzheimer disease. Nat Rev Neurol. 2010;6:78–87.

CAS  PubMed  Article  Google Scholar 

Veiga S, Rodríguez-Martín A, Garcia-Ribas G, Arribas I, Menacho-Román M, et al. Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers. Sci Rep. 2020;10:2138.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Calil V, Elliott E, Borelli WV, Barbosa B, Bram J, et al. Challenges in the diagnosis of dementia: Insights from the United Kingdom-Brazil Dementia Workshop. Dement Neuropsychol. 2020;14:201–8.

PubMed  PubMed Central  Article  Google Scholar 

Office for National Statistics (ONS). Overview of the UK population: January 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/articles/overviewoftheukpopulation/january2021. Accessed 31 Mar 2022.

AARP. The Aging Readiness & Competitiveness Report. https://arc.aarpinternational.org/countries/brazil. Accessed 31 Mar 2022.

Bullain S, Doody R. What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti-amyloid trials. J Neurochem. 2020;155:120–36.

CAS  PubMed  Article  Google Scholar 

Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, et al. Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement. 2019;15:106–52.

PubMed  Article  Google Scholar 

Arighi A, Carandini T, Mercurio M, Carpani G, Pietroboni AM, et al. Word and picture version of the free and cued selective reminding test (FCSRT): Is there any difference? J Alzheimers Dis. 2018;61:47–52.

PubMed  Article  Google Scholar 

Boada M, Ristic S, Pross N, Abi-Saab D, Bullain S, et al. Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer’s disease. Clin Neurophysiol. 2019;130:Abstract P37.

Article  Google Scholar 

Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384:1691–704.

CAS  PubMed  Article  Google Scholar 

Blennow K. A review of fluid biomarkers for Alzheimer’s disease: moving from CSF to blood. Neurol Ther. 2017;6:15–24.

PubMed  PubMed Central  Article  Google Scholar 

Cummings JL, Atri A, Ballard C, Boneva N, Frölich L, et al. Insights into globalization: Comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program. Alzheimers Res Ther. 2018;10:116.

PubMed  PubMed Central  Article  CAS  Google Scholar 

DiFrancesco JC, Longoni M, Piazza F. Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): Candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy. Front Neurol. 2015;6:207.

PubMed  PubMed Central  Article  Google Scholar 

Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79:13–21.

PubMed  Article  Google Scholar 

De Roeck EE, De Deyn PP, Dierckx E, Engelborghs S. Brief cognitive screening instruments for early detection of Alzheimer’s disease: A systematic review. Alzheimers Res Ther. 2019;11:21.

PubMed  PubMed Central  Article  Google Scholar 

Brodaty H, Connors MH, Loy C, Teixeira-Pinto A, Stocks N, et al. Screening for dementia in primary care: A comparison of the GPCOG and the MMSE. Dement Geriatr Cogn Disord. 2016;42:323–30.

PubMed